Brokers Offer Predictions for ADAP Q1 Earnings

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Adaptimmune Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst A. He expects that the biotechnology company will post earnings of ($0.18) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.50 price target on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Other equities research analysts have also issued reports about the stock. StockNews.com lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Guggenheim reduced their target price on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Adaptimmune Therapeutics has an average rating of “Buy” and an average target price of $3.16.

Adaptimmune Therapeutics Price Performance

Shares of NASDAQ:ADAP opened at $0.59 on Friday. The firm has a 50 day simple moving average of $0.88 and a 200-day simple moving average of $1.03. Adaptimmune Therapeutics has a twelve month low of $0.42 and a twelve month high of $2.05. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $150.02 million, a PE ratio of -2.67 and a beta of 2.26.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ADAP. Baillie Gifford & Co. increased its position in Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after acquiring an additional 1,626,657 shares during the period. Long Focus Capital Management LLC grew its stake in shares of Adaptimmune Therapeutics by 15.6% in the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after purchasing an additional 1,662,184 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Adaptimmune Therapeutics by 28.3% in the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after purchasing an additional 394,566 shares during the period. FMR LLC raised its stake in shares of Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after purchasing an additional 50,419 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares during the period. 31.37% of the stock is owned by hedge funds and other institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.